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Background 
Effective December 9, 2004 the FDA required 
that the following warning appear on all over-the-
counter aluminum-containing antiperspirant drug 
products: “Ask a doctor before use if you have 
kidney disease.”1  The antiperspirant active 
ingredients are salts or complexes of aluminum 
with chloride, chlorohydrate, chlorohydrex-glycol, 




The FDA’s concern is that people with renal 
dysfunction may not be aware that daily use of 
aluminum-containing antiperspirant products may 
put them at higher risk of kidney problems.1  
Transdermal absorption of aluminum can occur.3,4  
Those with normal renal function do not 
accumulate aluminum but excrete the small 
quantities absorbed via the urine.  Patients with 
diminished renal function tend to accumulate 
aluminum.  Elevated levels of aluminum may 
cause neurotoxicity, possibly by inhibition of 
neuronal microtubule formation and competition 
with cations.  Long-term effects can cause 
microcytic anemia, abnormal muscle tremor such 
as involuntary jerking movements, dementia, 
slurred speech, seizures, and osteomalacia.5 
Some nephrologists believe that this 
recommendation by the FDA is based on false 
assumptions that toxic amounts of aluminum may 
be absorbed through the skin.  Rather, the problem 
of aluminum accumulation in patients with kidney 
disease results from either oral aluminum-
containing antacids used as phosphate binders or 
from aluminum-contaminated sterile water used to 
prepare dialysate fluid.6 
The FDA requires aluminum-containing 
antacid products to be labeled with warnings of 
aluminum accumulation in patients with kidney 
disease.  Elevated plasma-aluminum levels result 
from prolonged use in patients with renal failure 
and can result in worsening of dialysis 
osteomalacia and encephalopathy.  Aluminum is 
not well removed by dialysis because of its 
protein binding.7   
Aluminum accumulation has been portrayed as 
a possible cause of Alzheimer’s and other 
diseases.  In the FDA’s review of numerous 
studies, they conclude that aluminum can be 
associated with recognizable specific neurologic 
effects with high-doses and long-term exposure.  
But the FDA considers the evidence insufficient 
to link aluminum to Alzheimer’s disease as well 
as Parkinson’s or amyotrophic lateral sclerosis.2  
Candy et al reported the accumulation of 
aluminum in renal failure patients with long-term 
exposure to aluminum-containing phosphate 
binder antacids.  Post mortem brain examinations 
showed correlations between brain-aluminum 
concentration and aluminum exposure levels.  
Yet, these patients did not have dialysis 
encephalopathy.8    
In a case-controlled study of 130 patient-
matched pairs the association between aluminum 
exposure and Alzheimer’s from lifetime use of 
antiperspirants and antacids was examined.  
Results from this study were inconclusive.9  In a 
review by Rowan it was concluded that the 
association between aluminum and Alzheimer’s is 
a controversial issue.10 
Despite the controversy of aluminum 
accumulation from long-term antiperspirant use 
and the potential for increased risk, it is a good 
reminder for people with hypertension or diabetes 
to have their kidney function checked.  Too often 
people are unaware of kidney problems.  Elevated 
blood pressure or diabetes may be initial signs of 
problems.   
Patients with suspected or diagnosed kidney 
problems should be encouraged to take non-
aluminum-containing antacids and to use 
deodorants.  Deodorants do not contain aluminum. 
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Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
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